Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Translating dosages from animal models to human clinical trials--revisiting body surface area scaling.

Blanchard OL, Smoliga JM.

FASEB J. 2015 May;29(5):1629-34. doi: 10.1096/fj.14-269043. Epub 2015 Feb 5. Review.

PMID:
25657112
2.

Enhancing the delivery of resveratrol in humans: if low bioavailability is the problem, what is the solution?

Smoliga JM, Blanchard O.

Molecules. 2014 Oct 24;19(11):17154-72. doi: 10.3390/molecules191117154. Review.

3.

Development of a lozenge for oral transmucosal delivery of trans-resveratrol in humans: proof of concept.

Blanchard OL, Friesenhahn G, Javors MA, Smoliga JM.

PLoS One. 2014 Feb 26;9(2):e90131. doi: 10.1371/journal.pone.0090131. eCollection 2014.

4.

Recent data do not provide evidence that resveratrol causes 'mainly negative' or 'adverse' effects on exercise training in humans.

Smoliga JM, Blanchard OL.

J Physiol. 2013 Oct 15;591(20):5251-2. doi: 10.1113/jphysiol.2013.262956. No abstract available.

5.

The planar cell polarity effector Fuz is essential for targeted membrane trafficking, ciliogenesis and mouse embryonic development.

Gray RS, Abitua PB, Wlodarczyk BJ, Szabo-Rogers HL, Blanchard O, Lee I, Weiss GS, Liu KJ, Marcotte EM, Wallingford JB, Finnell RH.

Nat Cell Biol. 2009 Oct;11(10):1225-32. doi: 10.1038/ncb1966. Epub 2009 Sep 20.

Supplemental Content

Loading ...
Support Center